Newly Developed Test Shows Promise for Assessing Metastasis Risk in Uveal Melanoma Patients
![](https://eyecancer.com/wp-content/uploads/2016/10/extrascleral-extension-150x150.jpg)
Castle Biosciences, Inc. recently launched a new test to help doctors better asses the risk of uveal melanoma metastasis. Uveal melanoma ranks as the most common eye cancer in adults. About half of patients diagnosed with uveal melanoma develop metastatic disease, primarily in the liver. Researchers have found gene expression levels of PRAME (Preferentially Expressed [..] Read More…